Maxim Group Has Lowered Expectations for Indaptus Therapeutics (NASDAQ:INDP) Stock Price

Indaptus Therapeutics (NASDAQ:INDP) had its price target trimmed by Maxim Group from $8.00 to $5.00 in a research note published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Indaptus Therapeutics in a research report on Wednesday, October 16th.

Indaptus Therapeutics Stock Performance

Indaptus Therapeutics stock opened at $1.11 on Wednesday. The stock has a fifty day moving average of $1.31 and a 200 day moving average of $1.82. The stock has a market cap of $11.32 million, a PE ratio of -0.65 and a beta of 1.45. Indaptus Therapeutics has a one year low of $1.03 and a one year high of $3.10.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.15. As a group, sell-side analysts predict that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned about 0.17% of Indaptus Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.